港股異動丨復星醫藥AH齊漲 子公司研發新冠肺炎新藥獲美國FDA同意開展臨牀試驗
格隆匯10月9日丨復星醫藥(02196.HK)漲逾3%,復星醫藥(600196.SH)則漲超4%。中國復星醫藥週四宣佈,其控股子公司近日收到美國食品藥品監督管理局(FDA)同意旗下一隻用於治療新冠病毒肺炎的新藥進行臨牀試驗的函件,並擬於近期具備條件後在美國開始一期臨牀試驗。公司的聲明稱,該新藥為抗S1全人源單克隆中和抗體HLX70,用於治療新冠肺炎及由該病毒引起的急性呼吸窘迫綜合症或多重器官衰竭。該新藥基於復星醫藥控股子公司上海復宏漢霖生物技術,於今年5月與三優生物醫藥(上海)、上海之江生物科技達成的合作開發協議進行研發。截至今年8月,集團對該新藥的累計研發投入約1520萬元人民幣。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.